Jerome B. Zeldis - 02 Jan 2026 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Reporting relationship: Director
Issuer ticker: PTCT
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jan 2026, 17:20:21 UTC
Prior SEC filing: 27 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Avraham S. Adler, Attorney-in-Fact

Key filing fact

Jerome B. Zeldis filed Form 4 for PTC THERAPEUTICS, INC. (PTCT) on 06 Jan 2026.

Key facts

This page summarizes Jerome B. Zeldis's Form 4 filing for PTC THERAPEUTICS, INC. (PTCT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jan 2026, 17:20.

Change

Previous filing in this sequence was filed on 27 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001433982 Primary reporting owner

ZELDIS JEROME B

Relationship: Director
Address: C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN
Signature: /s/ Avraham S. Adler, Attorney-in-Fact
Signature date: 06 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PTCT transaction

Common Stock

Award

Transaction value: $0
Shares: +4,000
Change %: +22%
Price: $0.000000
Shares after: 22,500
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PTCT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +3,475
Change %
Price: $0.000000
Shares after: 3,475
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,475
Exercise price: $76.74
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (i) four years from the date of grant and (ii) the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death.

Footnote F2

This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026.